Research programme: anti-inflammatory antibodies - Light Chain Bioscience/Tiziana
Alternative Names: NI-1201/α-IL-6RcLatest Information Update: 28 Jul 2021
At a glance
- Originator NovImmune SA
- Developer Tiziana Life Sciences
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Inflammation in United Kingdom (Parenteral)
- 11 Mar 2020 Tiziana Life Sciences plans a clinical trial for Coronavirus in United Kingdom
- 07 Jun 2018 Preclinical development is ongoing in United Kingdom